Disease Prevention

Omicron is already changing how medicine fights COVID-19.

Although it only became widespread across the United States in the past week, doctors, pharmacists and drug companies said they need different tools against the new variant.

Two well-used monoclonal antibodies are unlikely to be effective against omicron. In their place, the government accelerated authorization of two antivirals that can be taken right after diagnosis to prevent illnesses from becoming severe.

The Food and Drug Administration on Wednesday authorized use of Pfizer's Paxlovid, a series of pills, taken at home that prevent nearly 90% of severe COVID-19 among those at high risk. On Thursday, the FDA authorized use of a second antiviral, molnupiravir, which appears to prevent progression to severe disease about 30% of the time.

"As we face omicron, the nation's medicine cabinet of treatments gives us more options to protect the American people," said Jeff Zients, the White House Coronavirus Response Coordinator. "We have tools to keep people safe and we will continue to use them."

Israel set to offer fourth dose of COVID-19 vaccine to people over 60 Israel announced on Tuesday that it will offer a fourth dose of the COVID-19 vaccine to people older than 60, amid concern about the spread of the Omicron variant of the coronavirus. Reuters Reuters

...

Biden steps up the U.S. pandemic response with help for hospitals and expanded testing

Facing an alarming surge in coronavirus cases that threatens to overwhelm the nation’s hospital system, President Biden stepped up his administration’s pandemic response again on Tuesday and tried to reassure an anxious nation, telling Americans that “we should all be concerned about Omicron, but not panicked.”

In a White House address, Mr. Biden directed his defense secretary to get 1,000 military medical professionals ready to help where needed; he announced new vaccination and testing sites; and he said his administration was buying 500 million rapid Covid-19 tests to distribute free to the public beginning in January through a new website.